Items per page
Sort by

Send to:

Choose Destination

Results: 6


Huntington disease iPSCs show early molecular changes in intracellular signaling, the expression of oxidative stress proteins and the p53 pathway.

Szlachcic WJ, Switonski PM, Krzyzosiak WJ, Figlerowicz M, Figiel M.

Dis Model Mech. 2015 Jun 18. pii: dmm.019406. [Epub ahead of print]


A new humanized ataxin-3 knock-in mouse model combines the genetic features, pathogenesis of neurons and glia and late disease onset of SCA3/MJD.

Switonski PM, Szlachcic WJ, Krzyzosiak WJ, Figiel M.

Neurobiol Dis. 2015 Jan;73:174-88. doi: 10.1016/j.nbd.2014.09.020. Epub 2014 Oct 7.


Mouse models of polyglutamine diseases: review and data table. Part I.

Figiel M, Szlachcic WJ, Switonski PM, Gabka A, Krzyzosiak WJ.

Mol Neurobiol. 2012 Oct;46(2):393-429. doi: 10.1007/s12035-012-8315-4. Epub 2012 Sep 7. Review.


Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.

Switonski PM, Szlachcic WJ, Gabka A, Krzyzosiak WJ, Figiel M.

Mol Neurobiol. 2012 Oct;46(2):430-66. doi: 10.1007/s12035-012-8316-3. Epub 2012 Sep 4. Review.


An evaluation of oligonucleotide-based therapeutic strategies for polyQ diseases.

Fiszer A, Olejniczak M, Switonski PM, Wroblewska JP, Wisniewska-Kruk J, Mykowska A, Krzyzosiak WJ.

BMC Mol Biol. 2012 Mar 7;13:6. doi: 10.1186/1471-2199-13-6.


Mouse ataxin-3 functional knock-out model.

Switonski PM, Fiszer A, Kazmierska K, Kurpisz M, Krzyzosiak WJ, Figiel M.

Neuromolecular Med. 2011 Mar;13(1):54-65. doi: 10.1007/s12017-010-8137-3. Epub 2010 Oct 14.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk